Abstract
In addition to the classical neurotransmitters, acetylcholine and noradrenaline, a wide number of peptides with neurotransmitter activity have been identified in the past few years. Among them, the tachykinins substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) appear to act as mediators of nonadrenergic, noncholinergic (NANC) excitatory neurotransmission. Tachykinins interact with specific membrane proteins, belonging to the family of G protein-coupling cell membrane receptors. Until now, three tachykinin receptors termed NK1 (NK1R), NK2 (NK2R) and NK3 (NK3R) have been cloned in different species. A large amount of reports suggests that these peptides are involved in nociception and neuroimmunomodulation, and in the development of different diseases such as bronchial asthma, inflammatory bowel syndrome and psychiatric disorders. Tachykinin receptor antagonists are therefore promising, therapeutically relevant agents. However, and in spite of extensive research, the obtention of selective antagonists of tachykinin receptors have revealed very difficult. An understanding of how ligands interact with their receptors is essential to permit a rational design of compounds acting selectively at the tachykinin receptor level. The major aim of the present article is to review the structure-activity data that exist for tachykinins and their receptors, with the purpose of getting insight into basic structural requirements that determine ligand / receptor interaction.
Keywords: tachykinins, tachykinin receptors, substance p, neurokinin a, neurokinin b, hemokinin-1
Current Medicinal Chemistry
Title: Tachykinins and Tachykinin Receptors: Structure and Activity Relationships
Volume: 11 Issue: 15
Author(s): T. A. Almeida, J. Rojo, P. M. Nieto, F. M. Pinto, M. Hernandez, J. D. Martín and M. L. Candenas
Affiliation:
Keywords: tachykinins, tachykinin receptors, substance p, neurokinin a, neurokinin b, hemokinin-1
Abstract: In addition to the classical neurotransmitters, acetylcholine and noradrenaline, a wide number of peptides with neurotransmitter activity have been identified in the past few years. Among them, the tachykinins substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) appear to act as mediators of nonadrenergic, noncholinergic (NANC) excitatory neurotransmission. Tachykinins interact with specific membrane proteins, belonging to the family of G protein-coupling cell membrane receptors. Until now, three tachykinin receptors termed NK1 (NK1R), NK2 (NK2R) and NK3 (NK3R) have been cloned in different species. A large amount of reports suggests that these peptides are involved in nociception and neuroimmunomodulation, and in the development of different diseases such as bronchial asthma, inflammatory bowel syndrome and psychiatric disorders. Tachykinin receptor antagonists are therefore promising, therapeutically relevant agents. However, and in spite of extensive research, the obtention of selective antagonists of tachykinin receptors have revealed very difficult. An understanding of how ligands interact with their receptors is essential to permit a rational design of compounds acting selectively at the tachykinin receptor level. The major aim of the present article is to review the structure-activity data that exist for tachykinins and their receptors, with the purpose of getting insight into basic structural requirements that determine ligand / receptor interaction.
Export Options
About this article
Cite this article as:
Almeida A. T., Rojo J., Nieto M. P., Pinto M. F., Hernandez M., Martín D. J. and Candenas L. M., Tachykinins and Tachykinin Receptors: Structure and Activity Relationships, Current Medicinal Chemistry 2004; 11 (15) . https://dx.doi.org/10.2174/0929867043364748
DOI https://dx.doi.org/10.2174/0929867043364748 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Nanocarriers-based Approaches to Diagnose and Red uce Vascular Inflammation in Atherosclerosis
Current Medicinal Chemistry Prevention and Management of Hypertension Without Drugs
Current Hypertension Reviews Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design Probenecid: An Emerging Tool for Neuroprotection
CNS & Neurological Disorders - Drug Targets Pandemic of Atopic Diseases - A Lack of Microbial Exposure in Early Infancy?
Current Drug Targets - Infectious Disorders Cysteinyl Leukotriene Receptor Antagonists and Thromboxane Synthase Inhibitors: New Targets to Treat Asthma
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Preliminary Study of microRNAs Allele-specific Targeting in Allergic Rhinitis Patients from Central China
Combinatorial Chemistry & High Throughput Screening SUBJECT INDEX TO VOLUME 1
Current Drug Safety Nanosuspension: A Potential Nanoformulation for Improved Delivery of Poorly Bioavailable Drug
Micro and Nanosystems Simultaneous Determination of Doxofylline and its Metabolite Theophylline in Rat Plasma by Ultra Performance Liquid Chromatography
Current Pharmaceutical Analysis Current Concepts for Optimizing the Therapeutic Index of Glucocorticoid Receptor Ligands for Oral and Inhalative Use: Basic Considerations and Clinical Reality
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Adverse Drug Reactions and Safety Considerations of NSAIDs: Clinical Analysis
Current Drug Safety A Glance on the Role of Bacterial Siderophore from the Perspectives of Medical and Biotechnological Approaches
Current Drug Targets Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal MAPKs as Mediators of Cell Fate Determination: an Approach to Neurodegenerative Diseases
Current Medicinal Chemistry Potential Application of Centrifuges to Protect the CNS in Space and on Earth
Current Alzheimer Research Modified Recombinant Allergens for Safer Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) Impurity Profile of Bronchodilators used in Asthma: A Critical Review
Current Drug Discovery Technologies New Treatments for Allergy: Advances in Peptide Immunotherapy
Current Medicinal Chemistry An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions
Current Pharmaceutical Design